Ciaran Murray is the Chief Executive Officer of ICON. He joined ICON as Chief Financial Officer in 2005, serving in that capacity until his appointment as Chief Executive. Prior to joining ICON, he held a number of senior financial positions in global organisations including Kraft Foods. Novell Inc. Northern Foods and Codec Systems.
He graduated with a Bachelor of Commerce degree from the University College Dublin and qualified as a Chartered Accountant with PwC
Brendan served as acting Chief Financial Officer since October 2011. He was appointed Chief Financial Officer in February 2012 prior to this he served as ICON’s Senior Vice President of Corporate Finance and he has been a senior member of the ICON finance team since January 2006.
Prior to joining ICON, Brendan held a senior corporate finance position in CRH plc, a major international building materials group. Brendan qualified as a Chartered Accountant with PricewaterhouseCoopers and obtained a Bachelor’s degree in Accounting and Finance from Dublin City University.
Dr. Steve Cutler was appointed Group President, Clinical Research Services in November 2011.
Steve has over 23 years’ experience within the pharmaceutical and CRO industry and joined ICON from Kendle where he held the position of Chief Executive Officer, having previously served as Kendle’s Chief Operating Officer. Prior to Kendle, Steve spent 14 years with Quintiles where he served as Senior Vice President, Global Project Management; Senior Vice President, Clinical, Medical and Regulatory; Senior Vice President, Project Management - Europe; and Vice President, Oncology - Europe as well as regional leadership positions in South Africa and Australia. Prior to joining Quintiles, Steve held positions with Sandoz (now Novartis) in Australia and Europe. He holds a B.Sc. and a PhD from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).
Colin Stanley is President of DOCS. He has over 14 years of experience working in the CRO industry. He joined ICON as a Project Manager in 2001 and has since held a range of positions of increasing responsibility. Since January 2011 Colin held the position of Chief Operating Offer for DOCS returning from Asia where he was Vice President of Clinical Operations, Asia Pacific with responsibility for all projects and staff in the region. Previous to this he was Director of Clinical Operations based in the US and in 2005 he led IMPROVE, a global Initiative focused on process improvement across all aspects of ICON’s business. He has also held various positions in Data Management including Head of Data Management, Europe. Colin started his career in Data Management at Quintiles.
Colin holds a Bachelor’s Degree in Biotechnology from Dublin City University.
Dr. Mario Rocci joined ICON as the former CEO of Prevalere Life Sciences, Inc. (a wholly owned subsidiary of ICON plc) in 2008. He served as Executive Vice President of Global Bioanalytical Sciences, overseeing ICON’s expanding Bioanalytical Sciences group, until his current appointment as President, ICON Development Solutions.
Mario's 29 years of industry experience includes positions such as Head of the Laboratory of Investigative Medicine and Research Associate Professor of Medicine at Thomas Jefferson University, where he was part of a team of Clinical Pharmacologists conducting Phase I-IV clinical studies on drugs undergoing development. Dr. Rocci was also a Clinical Associate Professor of Pharmacy Practice at the Philadelphia College of Pharmacy and Science.
Actively involved in the industry, Dr. Rocci served as the 2004 President of the American Association of Pharmaceutical Scientists (AAPS), a professional society of over 12,000 members, having previously been elected to a three year term on the AAPS Board of Directors. He also serves on the Board of Directors for the International Pharmaceutical Federation (FIP) and is Chairman of the Board of the Product Quality Research Institute (PQRI). He has authored over 125 scientific publications and has extensive experience in the pharmaceutical sciences and the regulatory requirements of the FDA.
Dr. Rocci earned a Ph.D. in Pharmaceutics and a B.S. in Pharmacy from the State University of New York at Buffalo.
Professor Buckley is ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters and he will also provide guidance and oversight to the medical and scientific groups across ICON.
An endocrinologist with over 30 years’ experience, Brendan joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and Senior Vice President of Medical Affairs. Brendan has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards for medium to large cardio-metabolic and rare disease clinical studies. Brendan is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and has also been director of the university’s European Center for Clinical Trials in Rare Diseases. He has been a board member of the Irish Medicines Board and of theEuropean Medical Agency (EMA)’s Scientific Advisory Group for Diabetes and Endocrinology since 2005. He was also a member of the EMA Committee for Orphan Medicinal Products from 2000-2003 and a member of the EMA’s panel of experts. Professor Buckley is also chairman of the Irish Statutory Anti-Doping Agency and is a member of the UK Anti-Doping Scientific Advisory Board.
Diarmaid Cunningham is ICON's General Counsel. Diarmaid joined ICON as General Counsel in November 2009 having spent 10 years with A&L Goodbody which is one of Ireland's premier corporate law firms. Diarmaid was appointed Company Secretary in October 2011.
Diarmaid graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997 and qualified as a Solicitor with A&L Goodbody in 2001.
Eimear is ICON's Executive Vice President of Human Resources. She has held various HR VP roles across the global business since joining ICON in 1999. Prior to joining ICON, Eimear led the HR function at GE Global Consumer Finance (Ireland). Eimear holds a BA Hons in business and is a qualified HR professional. She is an active member of the Chartered Institute of Personnel and Development and the Institute of Directors.
In his role as Executive VP of Quality and Compliance, Dr. Neil McCullough will provide strategic direction for quality management & quality assurance across all lines of business, ensuring full compliance with global regulations guiding the biopharmaceutical industry.
Neil brings to ICON over 22 years of leading quality functions for global pharmaceutical and clinical research organisations. Prior to ICON, Neil led the global quality and compliance division of PPD, before which he spent nine years at Pfizer Inc. as a member of the Pfizer Global Medical Quality Assurance Leadership team. Prior to Pfizer, Neil served as a quality consultant to GlaxoSmithKline's division of manufacturing.
Neil earned his doctorate in chemistry from the University of Kent at Canterbury in the UK and his masters in pharmaceutical medicine from Hibernia College, Dublin, in partnership with Harvard University and the Royal College of Physicians, Ireland.
Simon Holmes serves as Executive Vice President Investor Relations and Corporate Development. In this role, Simon has responsibility for ICON's strategy development, merger and acquisition activity and also leads ICON's engagement with investors.
Mr. Holmes joined ICON in 2005 and prior to his current role, he served as ICON's Executive Vice President Group Marketing and Market Development. Mr. Holmes has held senior positions within Microsoft, LogicaCMG and Cable and Wireless.
A graduate of the University of East Anglia and Cambridge University Mr. Holmes holds an MBA from the UCD Smurfit Business School.
Tom is ICON's Chief Information officer previous to this he held the position of President of ICON Central Laboratories.
He joined the company in Feb-2001 as Manager of Data management in Dublin, he subsequently went on to set-up ICON's process improvement initiative "IMPROVE" and returned to Data Management to become EU VP of Data Management before becoming Global Head of Data Management in 2006.
From 1994-2001 he worked for SmithKline Beecham and later GlaxoSmithKline and held positions in Data Management, Project Management and resource Management. He is a graduate of Kingston University in Surrey and a Member of the Royal Society of Chemistry. He holds a Degree in Medicinal Chemistry and a Masters in Data Management.